Key Highlights:
- BIO-key shares rose 29.19% to $3.54 on Friday, October 23, 2026.
- Second-quarter revenue rose 13% to $1,919,991, with license fees up 53% to $1,229,345.
- Gross margin widened to 87% from 73% a year earlier.
- The net loss narrowed to $576,852 from $1,167,396 in the second quarter of 2025.
- Cash and equivalents were $1,379,300 on June 30, and management says cash exceeded $4.5 million after a warrant inducement.
BIO-key Stock: Why Is the Penny Stock Up 29% on October 23, 2026?
BIO-key (NASDAQ:BKYI) shares rose 29.19% to $3.54 on Friday, October 23, 2026. The company has not announced a catalyst for the session, and its latest dated disclosure is its second-quarter report from August 13.
The move follows a turbulent year for the shares. Trading resumed on the Nasdaq Capital Market on July 8, 2026, after a hearings panel found that the company had regained compliance with minimum bid price and filing standards. A 1-for-10 reverse stock split took effect on April 30, 2026, so per-share figures reflect the split.
BIO-key sells biometric identity and access software, and the company says its technology secures access for more than forty million users. Customers include government, defense and financial sector organizations.
BIO-key Financials: What Did the Second-Quarter Report Show?
Revenue rose 13% to $1,919,991 from $1,696,907 in the second quarter of 2025. License fees grew 53% to $1,229,345, and gross profit was $1,674,040.
Gross margin reached 87%, up from 73% a year earlier. The net loss narrowed by about 51% to $576,852, or $0.56 per share, compared with a loss of $1,167,396, or $2.01 per share.
Cash and equivalents were $1,379,300 on June 30. After a warrant inducement that raised about $2.5 million gross earlier in August, the company said cash exceeded $4.5 million.
Is the Company on Track for Second-Half Profitability?
Management targets revenue growth and profitability in the second half of 2026 but has not given numeric guidance for the period. A hardware order of roughly $0.8 million, carrying a 100% gross profit contribution, slipped from the second quarter and is now expected to ship in the second half.
The first half fell short of the outlook given in May. The company guided to about $5 million of revenue for the half, while the two reported quarters total $4,065,524 (calculated, from $2,145,533 in the first quarter and $1,919,991 in the second).
The first-half net loss was $741,888 (calculated, from $165,036 and $576,852), compared with a $1.9 million loss in the first half of 2025. The company had expected the half to be profitable.
What Do the Balance Sheet and Trading Status Mean for Investors?
Stockholders' equity was $7,432,013 at the end of March, the most recent figure in the first-quarter release. The company remains under a Discretionary Panel Monitor until July 6, 2027.
That monitor, combined with a small cash base and a recent warrant inducement, keeps the focus on whether second-half revenue arrives as planned. The company has not published a market capitalization figure in its releases.
What to Watch Next: Can BIO-key Deliver the Second-Half Targets?
BIO-key rose 29.19% on October 23 without an announced catalyst, so the move rests on a narrower loss, a higher gross margin and a Nasdaq return that is still under monitoring. The next dated checkpoint is third-quarter results; the company has not announced a date, and it reported the second quarter on August 13.
Shares rose 29.19% to $3.54, and the company has not announced a catalyst for the session.
Revenue rose 13% to $1,919,991, gross margin reached 87%, and the net loss narrowed to $576,852.
Trading resumed on the Nasdaq Capital Market on July 8, 2026.






Please wait processing your request...